Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression.
about
Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approachesIdentification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome.PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI.Catastrophic antiphospholipid syndromes in systemic lupus erythematosus.Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule.Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways.Placentation, antiphospholipid syndrome and pregnancy outcome.The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in ColombiansThe role of tissue factor in the antiphospholipid syndrome.Role of tissue factor in thrombosis in antiphospholipid antibody syndrome.Differential regulation of proinflammatory mediators following LPS- and ATP-induced activation of monocytes from patients with antiphospholipid syndrome.Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functionsIVIG in APS pregnancy.Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome.A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C.Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies.Antiphospholipid syndrome and tissue factor: a thrombotic couple.Is there a microangiopathic antiphospholipid syndrome?Evaluation of the hypolipidemic activity of 6,7-dimethoxycoumarin on placental tissue factor mRNA expression in experimental anti-phospholipid syndrome.Immunomodulatory effects of therapeutic plasma exchange on monocytes in antiphospholipid syndrome.Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases.Some antiphospholipid antibodies bind to hemostasis and fibrinolysis proteases and promote thrombosis.Tissue factor in the antiphospholipid syndrome.Recent advances in understanding antiphospholipid syndrome.C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodiesThe clinical significance of anticardiolipin antibody levels in patients with acute myocardial infarction: a regional study.Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome.Proteomics in antiphospholipid syndrome: a review.Potential use of statins in the treatment of antiphospholipid syndrome.The use of heparin for preventing miscarriage.Proteomic analysis of venous thromboembolism: an update.Biomarkers for cardiovascular risk assessment in autoimmune diseases.Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome.Phospholipid scramblase 1 expression is enhanced in patients with antiphospholipid syndrome.Effects of anti-β2-glycoprotein I antibody on PlGF, VEGF and sVEGFR1 production from cultured choriocarcinoma cell line.Adverse pregnancy outcome in the antiphospholipid syndrome: focus for future research.Dimerized Domain V of Beta2-Glycoprotein I Is Sufficient to Upregulate Procoagulant Activity in PMA-Treated U937 Monocytes and Require Intact Residues in Two Phospholipid-Binding Loops.Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus.Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins.Clotting, immune system, and venous thrombosis in lung adenocarcinoma patients: a prospective study.
P2860
Q28075691-F7F96247-DAF9-4A72-B08C-1E8C20FE4275Q30896030-75992E84-7DC7-4F2E-803E-279C3E4D742FQ33400120-0D60E288-D450-4D83-9945-320BE9DBBC81Q33536795-26368F01-594B-43E3-A410-30013BEE31CBQ33741075-4AD79074-8345-4AC2-A291-B05C5372191DQ33967600-140560B3-24A5-4C8B-8778-C3E577570BEDQ34173981-BEAA3F4B-C870-49D5-BAEC-4117CBD88BF3Q34400681-A19CC8A8-15B6-44B2-A8D4-59C65C1E4BF5Q34441079-61D29CD2-6C60-487C-B520-FAA936675B8BQ34676688-92650083-B63B-43CE-8589-491139FD1F9CQ35133146-64A70680-75B7-43A9-B5CB-4903A9623367Q35214718-5EFFB0D1-B20A-4FAB-A4D0-7FED11D4323BQ35918396-25276E3D-84C8-48AD-B70F-0E6BC7766B82Q35953541-0E11C5E9-CBFC-4800-9864-C6BB5D52D269Q35995065-4796D4CE-EA23-4105-99DA-0F22EF373517Q36287542-CAD80322-0A1E-4F13-B8A4-5EDA72364D6BQ36458154-4A94928D-296E-4C29-8293-25BF20D7AC6AQ36759849-80A2F5EA-B845-4D8E-996D-AD2C04BFF20CQ37067071-84837E2E-7E3D-4CC2-BB11-6DC5726C6D3FQ37107209-C262F91F-90ED-4559-9CE1-07C34C35CF5BQ37283020-F8E38051-2FDF-4C2E-8A4D-B7B8DACCA8F3Q37283026-ED9433D0-9357-429D-BC3D-771A90626AFFQ37283046-2A2E8244-6E64-4EE6-9436-B5B0BE5F0C20Q37577693-E4461149-E26E-4AA1-A8DB-95F611E1AE75Q37581827-AE69753C-A0EE-4C57-B23B-DA89F294F6A9Q37589607-88CA4F65-36D8-45C8-A6A4-AC466D0096A1Q37634423-747224E0-EFF3-4938-9C03-CD196A8B1032Q37721600-25AB15CA-2DFC-46B7-8AC6-781FBBD525DFQ37959316-5BD621E5-A6E1-4A11-9914-CEA6C7E06998Q37995711-7613AA49-63E0-4E45-82FD-0E335D170AAEQ38097846-3ACB59F5-226B-4F8E-8B15-76C7EF501976Q38293735-0F4A1D04-A988-41A2-989D-170232E84CDCQ38333095-E84444DE-2434-4309-8D78-7A4AAC348546Q39360288-1DBDA6E9-13E9-4DF8-907A-C62AD0B63623Q39557076-8CBBF72A-7AAD-4CA2-A1FD-E2A6D68A067BQ40910137-BF5A8D12-7C13-4CA2-B6F5-508809387503Q41103646-3B07A86C-BB3D-435B-B876-FF26A068BE35Q42647843-C9DB3F50-1C67-4077-8B37-705DA7F13C42Q43120462-F0A5D169-BBA7-4FCC-BA69-1A3388F07C81Q43411494-81F19F1A-69D0-41E1-A135-9AFFCE7FFEEC
P2860
Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression.
description
1997 nî lūn-bûn
@nan
1997 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Thrombosis in primary antiphos ...... cyte tissue factor expression.
@ast
Thrombosis in primary antiphos ...... cyte tissue factor expression.
@en
type
label
Thrombosis in primary antiphos ...... cyte tissue factor expression.
@ast
Thrombosis in primary antiphos ...... cyte tissue factor expression.
@en
prefLabel
Thrombosis in primary antiphos ...... cyte tissue factor expression.
@ast
Thrombosis in primary antiphos ...... cyte tissue factor expression.
@en
P2093
P356
P1476
Thrombosis in primary antiphos ...... cyte tissue factor expression.
@en
P2093
Cuadrado MJ
López-Pedrera C
Tinahones F
P2860
P304
P356
10.1002/ART.1780400509
P577
1997-05-01T00:00:00Z